NCT02005289View on ClinicalTrials.gov

Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

January 17, 2014

Primary Completion Date

August 25, 2025

Study Completion Date

December 15, 2025

Conditions
Contiguous Stage II Small Lymphocytic LymphomaNoncontiguous Stage II Small Lymphocytic LymphomaProlymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaStage I Chronic Lymphocytic LeukemiaStage I Small Lymphocytic LymphomaStage II Chronic Lymphocytic LeukemiaStage III Chronic Lymphocytic LeukemiaStage III Small Lymphocytic LymphomaStage IV Chronic Lymphocytic LeukemiaStage IV Small Lymphocytic Lymphoma
Interventions
BIOLOGICAL

MOR00208

Given by IV infusion

DRUG

lenalidomide

Given PO

OTHER

Correlative Studies

Correlative studies associated with this trial will focus on the effects of MOR00208 alone and in combination with lenalidomide on immune effector cell number and function.

Trial Locations (1)

43210

The Ohio State University Comprehensive Cancer Center, Columbus

Sponsors

Collaborators (1)

MorphoSys AG
All Listed Sponsors
collaborator

MorphoSys AG

INDUSTRY

lead

Ohio State University Comprehensive Cancer Center

OTHER